A phase-one probe study found increased midazolam area under the curve during rucaparib treatment. A change in total exposure was not mirrored by a similar increase in peak concentration.
Patients with advanced solid tumors received a probe-drug cocktail before and during steady-state rucaparib. Midazolam served as the CYP3A substrate; other probes assessed additional pathways.
The midazolam AUC ratio was 1.39, with a ninety-percent confidence interval of 1.14–1.68. Across the probe substrates, peak-concentration effects were limited. The investigators classified the CYP3A effect under the study conditions as weak inhibition.
AUC, peak concentration, and terminal behavior describe different parts of a concentration-time profile. A 39% AUC increase does not imply that every concentration rose by 39% or that sedation duration increased by the same percentage.
The single-sequence design, cancer population, specific rucaparib regimen, and probe doses limit extrapolation. This was not a driving or impairment trial and did not establish a clinical effect at every possible midazolam dose.
Identify which pharmacokinetic parameter changed and retain the confidence interval. The paper supports a pathway-specific interaction discussion, not a conclusion that the combination necessarily caused an adverse event or that all CYP3A substrates will change to the same extent.
Original analysis of the supplied journal article, identified as PMC6342242.